Escalated Dose of Irinotecan in mCRC

NCT02256800 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

213

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

GENETIC: UGT1A1 genotyping (6,6)
GENETIC: UGTIA1 genotyping (6,7)
GENETIC: UGTIA1 genotyping (7,7)
GENETIC: UGT1A1 non-genotyping
DRUG: bevacizumab (Avastin)
DRUG: irinotecan
DRUG: Leucovorin
DRUG: 5-FU

Sponsor

Jaw-Yuan Wang, MD, PhD